Eli Lilly and Company (LLY)
This Best-of-Class Pharma Stock Could Soar 72% This Year According to Wall Street Insider
Eli Lilly (NYSE: LLY) doesn't really need much of an introduction.
Stock Of The Day: Lilly's Strong Support Level Signals Potential Rebound
Shares of Eli Lilly and Company LLY are trading higher after getting pummeled on Friday. The move lower happened after the company announced preliminary sales that were less than expected.
Novo, Lilly Weight-Loss Drugs Reduce Risk of Alzheimer's, Study Shows. What It Means for the Stocks.
Weight-loss medications have exploded in popularity but the health-benefits go beyond obesity.
Eli Lilly: Market Overreacted
Eli Lilly's Q4 FY24 guidance adjustment is due to supply chain factors, not demand, creating an attractive buying opportunity with a 'Buy' rating. Despite a modest 0.6% revenue reduction, LLY still projects 32% growth for 2024, underscoring strong fundamentals and an impressive growth trajectory. The company's diverse portfolio, including Mounjaro and Zepbound, shows broad growth, with significant contributions from oncology and other therapeutic areas.
Should You Buy the Dip in Eli Lilly Stock Right Now?
2024 was an interesting year for pharmaceutical powerhouse Eli Lilly (LLY -4.21%). At one point, share prices had gained as much as 65% on the year.
Eli Lilly Missed Sales Expectations Again. Should Investors Be Worried?
In the first half of 2024, it seemed Eli Lilly (LLY -4.21%) could do no wrong. Unfortunately, the good times didn't last very long.
Could Donald Trump Make Eli Lilly Stock a No-Brainer Buy in 2025?
Eli Lilly (LLY 1.45%) began a roll in late 2020 that lasted almost four years. During that time, it became the world's largest healthcare company, with a market cap that topped $860 billion at one point.
FDA Okays LLY's Omvoh for Second Inflammatory Bowel Disease Condition
FDA approves Lilly's Omvoh for Crohn's disease, expanding its use to the second major type of IBD condition.
US FDA approves expanded use of Lilly's bowel disease drug
Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's disease, a type of chronic inflammatory bowel disease.
Eli Lilly: Big 2025 Ahead, But Execution Risks Exist
Eli Lilly: Big 2025 Ahead, But Execution Risks Exist
Eli Lilly cuts Q4 sales forecast, but analyst remains bullish on stock—here's why
Eli Lilly (LLY) reduced its fourth-quarter sales guidance by 5%, lowering expectations to $13.5 billion. This figure is $400 million below the low end of the company's prior guidance and includes $3.5 billion from its type 2 diabetes drug Mounjaro and $1.9 billion from its weight-loss medication Zepbound.
Eli Lilly Cuts Q4 Sales Forecast: ETFs to Buy on the Dip
Eli Lilly slashes the revenue guidance for the fourth quarter and fiscal 2024 but offers a bullish outlook for 2025.
